Emerging evidence suggests that MetS contributes to pain catastrophizing, with obesity acting as a key amplifier of pain perception in inflammatory diseases such as PsA ( In addition to psoriatic disease, GLP-1RAs are currently under investigation in other immune-mediated inflammatory diseases (IMIDs), such as inflammatory bowel disease, RA, and systemic lupus erythematosus ( Several clinical trials registered on ClinicalTrials.gov support the growing scientific interest in the repurposing of GLP-1RAs for psoriatic disease
Ive heard of Ozempic face, Ozempic butt
Kadowaki T, Isendahl J, Khalid U, et al
Hi not sure if this is still relevant to you
The investment bank also expects the adoption of these treatments to reach about 31.5 million people in the U.S., about 9% of the nations population, by 2035.